Avita Medical Inc. logo

Avita Medical Inc. (RCEL)

Market Open
3 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
5. 42
+0.25
+4.84%
$
143.28M Market Cap
- P/E Ratio
0% Div Yield
212,500 Volume
- Eps
$ 5.17
Previous Close
Day Range
5.31 5.53
Year Range
4.71 14.16
Want to track RCEL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 30 days
Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals

Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals

On Tuesday, Avita Medical, Inc. RCEL revised its revenue guidance for the fourth quarter and full year of 2024.

Benzinga | 6 months ago
Avita Medical price target lowered to $14 from $20 at Lake Street

Avita Medical price target lowered to $14 from $20 at Lake Street

Lake Street analyst Brooks O'Neil lowered the firm's price target on Avita Medical to $14 from $20 and keeps a Buy rating on the shares after the company announced preliminary Q4 commercial revenue that was below the firm's estimate and consensus and management lowered the expected FY24 revenue outlook. The company also provided initial FY25 revenue guidance that was below the firm's previous revenue estimate, which Lake Street calls "disappointing." However, with shares off nearly 22% in the after hours, the firm is maintaining a Buy rating as it continues to think this is a significant year for Avita, the analyst added.

Thefly | 6 months ago
AVITA Medical's shares sink 19% after another forecast cut

AVITA Medical's shares sink 19% after another forecast cut

AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters and pushed out its profitability target.

Reuters | 6 months ago
AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

AVITA Medical expects fourth quarter 2024 commercial revenue of approximately $18.4 million, reflecting growth of around 30% over the same period in 2023.

Globenewswire | 6 months ago
AVITA Medical Just Tripled Its TAM In The Burn Market

AVITA Medical Just Tripled Its TAM In The Burn Market

AVITA Medical's Q3 report showed strong sequential sales growth and a lower burn rate. My confidence in it reaching breakeven by Q3 2025 has increased. The transition to RECELL GO has been highly successful, with 75% of the US sales base switching from the manual version. This is driving increased utilization. The total addressable market for AVITA's new ecosystem of products has expanded significantly, with the burning market TAM increasing from $450 million to $1.5 billion.

Seekingalpha | 6 months ago
AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® mini.

Globenewswire | 6 months ago
AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDerm Cohealyx expected to triple AVITA Medical's addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Cohealyxâ„¢, a new collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences.

Globenewswire | 6 months ago
AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time.

Globenewswire | 7 months ago
AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand

AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand

VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a company specializing in commercial-stage regenerative medicine and pioneering devices for wound care management and skin restoration, today announced it has entered into an exclusive distribution agreement with Revolution Surgical Pty Ltd.

Globenewswire | 7 months ago
AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript

AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript

AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Ross Osborne - Cantor Fitzgerald Eric Anderson - TD Cowen John Hester - Bell Potter Chris Kallos - MST Access Operator Good day and thank you for standing by. Welcome to the AVITA Medical, Inc. Third Quarter 2024 Earnings Conference Call.

Seekingalpha | 8 months ago
AVITA Medical to Host Investor Webinar Briefing

AVITA Medical to Host Investor Webinar Briefing

VALENCIA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O'Toole, Chief Financial Officer, on November 12, 2024, at 2:00 p.m.

Globenewswire | 8 months ago
AVITA Medical Reports Third Quarter Financial Results

AVITA Medical Reports Third Quarter Financial Results

VALENCIA, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the third quarter ended September 30, 2024.

Globenewswire | 8 months ago
Loading...
Load More